Immune Checkpoint Inhibitor Therapy Aggravates T Cell–Driven Plaque Inflammation in Atherosclerosis

BACKGROUND: Immunotherapy has revolutionized cancer treatment. However, immune checkpoint inhibitors (ICIs) that target PD-1 (programmed cell death protein-1) and/or CTLA-4 (cytotoxic T lymphocyte-associated antigen-4) are commonly associated with acute immune-related adverse events. Accumulating ev...

Descripción completa

Detalles Bibliográficos
Autores principales: Poels, Kikkie, van Leent, Mandy M.T., Boutros, Celine, Tissot, Hubert, Roy, Séverine, Meerwaldt, Anu E., Toner, Yohana C.A., Reiche, Myrthe E., Kusters, Pascal J.H., Malinova, Tsveta, Huveneers, Stephan, Kaufman, Audrey E., Mani, Venkatesh, Fayad, Zahi A., de Winther, Menno P.J., Marabelle, Aurelien, Mulder, Willem J.M., Robert, Caroline, Seijkens, Tom T.P., Lutgens, Esther
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8352210/
https://www.ncbi.nlm.nih.gov/pubmed/34396271
http://dx.doi.org/10.1016/j.jaccao.2020.08.007

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8352210/
https://www.ncbi.nlm.nih.gov/pubmed/34396271
http://dx.doi.org/10.1016/j.jaccao.2020.08.007

Ejemplares similares